Drug Trial Radar · NCT00038948
Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients
Last checked: Nov 20, 2026Latest source record: May 14, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
830
Actual
Start
Jan 2002
Primary completion
May 2008
Study completion May 2008
Sponsor
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jun 7, 2002
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the effect of conversion from calcineurin inhibitor to sirolimus based therapy on renal function.
Conditions
- Renal Transplantation
Interventions
SirolimusDrug
Sirolimus, Cyclosporine A \& Tacrolimus are concentration controlled
tacrolimusDrug
Cyclosporine ADrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Nankivell Glomerular Filtration Rate (GFR)Time frame: 52 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.